JP2024539512A5 - - Google Patents

Info

Publication number
JP2024539512A5
JP2024539512A5 JP2024548515A JP2024548515A JP2024539512A5 JP 2024539512 A5 JP2024539512 A5 JP 2024539512A5 JP 2024548515 A JP2024548515 A JP 2024548515A JP 2024548515 A JP2024548515 A JP 2024548515A JP 2024539512 A5 JP2024539512 A5 JP 2024539512A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid vaccine
vaccine according
approximately
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047107 external-priority patent/WO2023069498A1/en
Publication of JP2024539512A publication Critical patent/JP2024539512A/ja
Publication of JP2024539512A5 publication Critical patent/JP2024539512A5/ja
Pending legal-status Critical Current

Links

JP2024548515A 2021-10-22 2022-10-19 Mrnaワクチン組成物 Pending JP2024539512A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163270964P 2021-10-22 2021-10-22
US63/270,964 2021-10-22
US202163290889P 2021-12-17 2021-12-17
US63/290,889 2021-12-17
US202263320647P 2022-03-16 2022-03-16
US63/320,647 2022-03-16
PCT/US2022/047107 WO2023069498A1 (en) 2021-10-22 2022-10-19 Mrna vaccine composition

Publications (2)

Publication Number Publication Date
JP2024539512A JP2024539512A (ja) 2024-10-28
JP2024539512A5 true JP2024539512A5 (cg-RX-API-DMAC10.html) 2026-01-26

Family

ID=84358887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548515A Pending JP2024539512A (ja) 2021-10-22 2022-10-19 Mrnaワクチン組成物

Country Status (6)

Country Link
US (1) US20250295755A1 (cg-RX-API-DMAC10.html)
EP (1) EP4419081A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539512A (cg-RX-API-DMAC10.html)
KR (1) KR20240090727A (cg-RX-API-DMAC10.html)
CA (1) CA3235867A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023069498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025515189A (ja) 2022-05-06 2025-05-13 セイル バイオメディシンズ インコーポレイテッド ポリペプチドを封入する複合脂質ナノ粒子およびその使用
WO2024220712A2 (en) * 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024260359A1 (zh) * 2023-06-20 2024-12-26 石药集团巨石生物制药有限公司 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025179198A1 (en) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Circular polyribonucleotides and unmodified linear rnas with reduced immunogenicity
WO2026152023A1 (en) 2025-01-10 2026-07-16 Sail Biomedicines, Inc. Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides
WO2026152164A1 (en) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ATE219660T1 (de) 1994-09-30 2002-07-15 Inex Pharmaceuticals Corp Mittel zum einbringen polyanionischer materialien in zellen
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US20170202979A1 (en) 2014-07-17 2017-07-20 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016187531A1 (en) 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2017176974A1 (en) 2016-04-06 2017-10-12 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2019027999A1 (en) 2017-07-31 2019-02-07 Ohio State Innovation Foundation BIOMIMETIC NANOMATERIALS AND USES THEREOF
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
US11622942B2 (en) 2017-11-14 2023-04-11 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
MX2021001979A (es) * 2018-08-24 2021-05-27 Flagship Pioneering Innovations Vi Llc Metodos y composiciones para la modificacion de plantas.
MX2021003455A (es) 2018-10-02 2021-09-21 Intellia Therapeutics Inc Lípidos con amina ionizables.
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN119285480A (zh) 2018-12-05 2025-01-10 英特利亚治疗股份有限公司 改性的胺脂质
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
US12409137B2 (en) 2019-08-24 2025-09-09 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs with charged lipids
WO2021154763A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202200199A (zh) 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法

Similar Documents

Publication Publication Date Title
JP7523897B2 (ja) 呼吸器合胞体ウイルス(rsv)ワクチン
US20260091101A1 (en) Bunyavirales vaccine
US10358630B2 (en) Recombinant influenza vectors with tandem transcription units
TW202140518A (zh) 冠狀病毒疫苗
US7723094B2 (en) Recombinant influenza vectors with a polII promoter and ribozymes for vaccines and gene therapy
CN110478479B (zh) 用于活的减毒病毒的方法和组合物
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
JP2012021030A (ja) 新規組成物
TW202333780A (zh) 冠狀病毒疫苗
JP2016106093A (ja) インフルエンザワクチンの製造方法
ES2689150T3 (es) Métodos para la prevención de agregación de componentes víricos
JP2004501639A5 (cg-RX-API-DMAC10.html)
JP2012510822A (ja) ウイルス増殖を誘導するための組成物、方法、および使用
Kopecky-Bromberg et al. Recombinant vectors as influenza vaccines
MX2024005482A (es) Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
TW202539697A (zh) 冠狀病毒疫苗
Binjawadagi et al. Mucosal delivery of recombinant vesicular stomatitis virus vectors expressing envelope proteins of respiratory syncytial virus induces protective immunity in cotton rats
CA2380514A1 (en) Attenuated influenza virus useful as vaccine
Mooney et al. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
Greer et al. Long‐term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus‐based replicon particles
JP2024543954A5 (cg-RX-API-DMAC10.html)
Elliott Bunyaviruses: general features
WO2025149907A1 (en) Influenza vaccines
WO2025052417A1 (en) Thermostable composition comprising vesiculo virus
WO2024174012A1 (pt) Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal